Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Approval paves the way for expansion in North America’s growing vascular access market, with innovative SlipStream technology designed to simplify catheter insertion and enhance patient care
Healthcare speed-scaling platform offers clinical validation, regulatory support, mentorship, and investor access to startups working across preventive health, oncology, genomics, diagnostics, and digital health
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
Exclusive partnership introduces globally benchmarked stem cell processing platform aimed at improving stem cell recovery, quality, and long-term therapeutic potential
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
